On 5 February 2024,
Novo Holdings announced a merger agreement with
Catalent Inc. (Catalent Pharma Solutions) to acquire the company in an all-cash transaction valued at USD 16.5 billion on an enterprise value basis. As part of the transaction, Novo Nordisk (CPH: NOVO-B) agreed to acquire three Catalent fill-finish sites from Novo Holdings for an upfront payment of USD 11 billion. This acquisition, on a stand-alone basis, is one of the largest ever made by a Danish company. The acquisition by Novo Holdings of Catalent Inc. and the related acquisition by Novo Nordisk of the three manufacturing sites from Novo Holdings were both completed on 18 December 2024.
Moalem Weitemeyer assisted Catalent Inc. with all Danish law aspects of the completion of both the acquisition by Novo Holdings and the related acquisition by Novo Nordisk of the three manufacturing sites. Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates served as global counsel for Catalent Inc., and we thank their team, led by Todd Freed and Patrick Lewis, for a strong collaboration.
We also extend our gratitude to Davis Polk & Wardwell LLP and Gorrissen Federspiel, representing the Novo side, for their excellent cooperation.
Finally, we are proud that Moalem Weitemeyer, through these two transactions and DSV - Global Transport and Logistics’ announced acquisition of DB Schenker, in 2024 has advised on the three largest acquisitions ever made by Danish companies.
